Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Shares of Akebia Therapeutics Inc. (AKBA) were down 7% to $14.40  in premarket trading on Thursday, June 29, on the heels of news after the market close on Wednesday that the Cambridge, Mass.-based firm had priced an underwritten public offering of 4 million shares at $14.50 a share, which would generate gross proceeds of $58 million. Akebia has also given underwriters a 30-day option to buy up to an additional 600,000 shares.

Akebia plans to use part of the net proceeds from the offering for the continued clinical development of its lead product candidate vadadustat, a potential treatment for anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company also plans to use the proceeds for additional manufacturing capabilities and for the clinical development of AKB-5169, among other corporate purposes.

Akebia expects the offering to close on July 5.

Meanwhile, shares of Sarepta Therapeutics Inc. (SRPT) rose nearly 3% to $34.85 after the Cambridge, Mass.-based company named former Allergan plc AGN executive Douglas S. Ingram as its new president and CEO. Ingram succeeds Edward M. Kaye, who in April notified the company he planned to resign.

Other biotech movers include Esperion Therapeutics Inc. (ESPR) . Shares of the Ann Arbor, Mich.-based firm rose nearly 3% to $49.69.

More from Health

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

How to Become a Physician Assistant: What to Know

How to Become a Physician Assistant: What to Know

What is THC? Experts Weigh in on the Compound's Benefits and Effects

What is THC? Experts Weigh in on the Compound's Benefits and Effects

How Much Does a Physician Assistant Make?

How Much Does a Physician Assistant Make?

Buy These 3 Risky Biotech Stocks

Buy These 3 Risky Biotech Stocks